Literature DB >> 23360631

Distribution of myofibroblast cells and microvessels around invasive ductal carcinoma of the breast and comparing with the adjacent range of their normal-to-DCIS zones.

Shahriar Dabiri1, Amin Talebi, Jahanbanoo Shahryari, Manzoumeh Shamsi Meymandi, Hossein Safizadeh.   

Abstract

BACKGROUND: This study seeks to determine the relationships between manifestation of myofibroblasts in the stroma tissue of hyperplastic pre-invasive breast lesions to invasive cancer by investigating clinicopathological data of patients, their effect on steroid receptor expression and HER2, and angiogenesis according to CD34 antigen expression.
METHODS: 100 cases of invasive ductal carcinoma were immunohistochemically investigated for the presence of smooth muscle actin (SMA), ER/PR, HER2, anti-CD34 antibody and microvessel count (MVC). Patients were scored in four different zones of invasive areas: invasive cancer, DCIS, fibrocystic disease ± ductal intraepithelial neoplasia (FCD ± DIN), and normal tissue.
RESULTS: There was a significant difference in stromal myofibroblasts between all areas except for the stroma of DCIS and FCD ± DIN (P < 0.001). We observed positive significant correlations between stromal myofibroblasts, HER2 expression, and the numbers of involved lymph nodes in invasive cancer, DCIS, and FCD ± DIN (P < 0.001). More myofibroblasts were present in grade III cases, with the least frequent observed among grade I cases in the stroma of those with invasive disease, DCIS, and FCD ± DIN (P < 0.001).  MVC was inversely related to stromal myofibroblasts in invasive cancer (P < 0.001) and DCIS (P < 0.001), whereas there was a positive correlation in the stroma of FCD ± DIN (P = 0.002) and normal areas (P = 0.054). There was a significant difference in MVC observed in all areas except for DCIS and FCD ± DIN (P < 0.001). We noted significant inverse correlations between MVC, HER2 expression, and the numbers of involved lymph nodes in invasive cancer and DCIS (P < 0.001). Most MVC were present in grade I, with the least frequent observed in grade III cases in the stroma of invasive cancer, DCIS and FCD ± DIN (P < 0.001).
CONCLUSION: Angiogenesis can be observed before any significant myofibroblastic changes in the pre-invasive breast lesions. The elevated content of myofibroblasts in stroma of tumor; probably may be a worse prognostic factor  and the steps from atypical epithelial hyperplasia to DCIS and then to the invasive carcinoma do not appear to be always part of a linear progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23360631     DOI: 013162/AIM.008

Source DB:  PubMed          Journal:  Arch Iran Med        ISSN: 1029-2977            Impact factor:   1.354


  5 in total

1.  A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

Authors:  Sergey Klimov; Islam M Miligy; Arkadiusz Gertych; Yi Jiang; Michael S Toss; Padmashree Rida; Ian O Ellis; Andrew Green; Uma Krishnamurti; Emad A Rakha; Ritu Aneja
Journal:  Breast Cancer Res       Date:  2019-07-29       Impact factor: 6.466

2.  Multi-Omics Marker Analysis Enables Early Prediction of Breast Tumor Progression.

Authors:  Haifeng Xu; Tonje Lien; Helga Bergholtz; Thomas Fleischer; Lounes Djerroudi; Anne Vincent-Salomon; Therese Sørlie; Tero Aittokallio
Journal:  Front Genet       Date:  2021-06-03       Impact factor: 4.599

Review 3.  Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go.

Authors:  Rachel J Buchsbaum; Sun Young Oh
Journal:  Cancers (Basel)       Date:  2016-01-27       Impact factor: 6.639

4.  Mesenchymal-epithelial signalling in tumour microenvironment: role of high-mobility group Box 1.

Authors:  Sikander Sharma; Andrew Evans; Elaine Hemers
Journal:  Cell Tissue Res       Date:  2016-03-16       Impact factor: 5.249

Review 5.  Metabolic Reprogramming of Cancer Associated Fibroblasts: The Slavery of Stromal Fibroblasts.

Authors:  Angelica Avagliano; Giuseppina Granato; Maria Rosaria Ruocco; Veronica Romano; Immacolata Belviso; Antonia Carfora; Stefania Montagnani; Alessandro Arcucci
Journal:  Biomed Res Int       Date:  2018-06-05       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.